ABBOTT PARK, Ill., June 14, 2017 — Abbott announced today that the Alinity hq analyzer for hematology is now CE Marked and available in Europe and other countries that recognize CE Mark. The analyzer ...

Abbott Laboratories is adding HPV screening to its "Alinity m" family of diagnostic assays following U.S. Food & Drug Administration approval. Abbott said in a press release that the FDA approved its ...

ABBOTT PARK, Ill., Nov. 2, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) has received U.S. Food and Drug Administration (FDA) approval for its molecular human papillomavirus or HPV screening solution, ...

The newly approved Alinity m high risk human papillomavirus (HPV) assay is indicated to detect HPV and for use in routine cervical cancer screening per professional medical guidelines. The FDA has ...

ABBOTT PARK, Ill., July 11, 2019 /PRNewswire/ -- Abbott (NYSE: ABT) announced today U.S. Food and Drug Administration (FDA) approval for its new blood and plasma screening Alinity™ s System. This new ...

The FDA urged clinical laboratories and healthcare providers to retest any patients who have recently received a positive result from two of Abbott’s PCR COVID-19 assays after identifying a heightened ...

New test will run on Abbott's Alinity® i laboratory instrument, complementing Abbott's rapid i-STAT TBI Plasma test, cleared by the FDA in 2021 Given the significant number of Alinity i instruments in ...

A month after Abbott issued a safety notice describing a defect that could cause some of its COVID-19 tests to return false positive results, the FDA has upgraded the issue into a Class I recall. In ...

Alinity, a family of next-generation clinical chemistry and immunoassay diagnostics from Abbott Laboratories (NYSE:ABT) is now being offered in Europe and other countries that distinguish the CE mark.

According to the U.S. Centers for Disease Control (CDC), most sexually active adults will experience HPV infections; new test detects those HPV genotypes that could lead to cancer Abbott (ABT)'s new ...